The effect of nafarelin, acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

C. A. Peters, Patrick Walsh

Research output: Contribution to journalArticle

Abstract

We examined the influence of androgens on benign prostatic hyperplasia, using nafarelin acetate, a potent luteinizing-hormone-releasing hormone agonist, to achieve reversible androgen deprivation in men with benign prostatic hyperplasia. Nine patients with bladder-outlet obstruction due to benign prostatic hyperplasia were treated with subcutaneous nafarelin acetate (400 μg per day) in a open trial for six months. In all patients, serum testosterone decreased to castrate levels. Objective observations included uroflowmetry, measurement of residual urine volume, determination of prostatic size by ultrasonography, and prostatic biopsy. In all patients, the prostate regressed to a mean (±SEM) of 75.8 ± 3 percent of the initial size (range, 52 to 86,; P <0.005); the regression reached a plateau after four months. Morphologic analysis of biopsy specimens showed regression of glandular epithelium. Three of ninbe patients had clinical improvement with treatment. Six months after the cessation of treatment, plasma testosterone levels had returned to normal and the size of the prostate had increased to 99 ± 5.5 percent of the initial size. These findings suggest that androgens have an important supportive role in established benign prostatic hyperplasia and that testicular suppression will benefit some patients. However, this form of treatment could be applicable only in carefully selected patients who were not surgical candidates, and it would need to be maintained indefinitely.

Original languageEnglish (US)
Pages (from-to)599-604
Number of pages6
JournalNew England Journal of Medicine
Volume317
Issue number10
StatePublished - 1987

Fingerprint

Nafarelin
Prostatic Hyperplasia
Gonadotropin-Releasing Hormone
Androgens
Testosterone
Prostate
Urinary Bladder Neck Obstruction
Biopsy
Withholding Treatment
Residual Volume
Ultrasonography
Epithelium
Urine
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of nafarelin, acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. / Peters, C. A.; Walsh, Patrick.

In: New England Journal of Medicine, Vol. 317, No. 10, 1987, p. 599-604.

Research output: Contribution to journalArticle

@article{c2afcd2f6bff4d2d80994b2a5aa6ea0a,
title = "The effect of nafarelin, acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia",
abstract = "We examined the influence of androgens on benign prostatic hyperplasia, using nafarelin acetate, a potent luteinizing-hormone-releasing hormone agonist, to achieve reversible androgen deprivation in men with benign prostatic hyperplasia. Nine patients with bladder-outlet obstruction due to benign prostatic hyperplasia were treated with subcutaneous nafarelin acetate (400 μg per day) in a open trial for six months. In all patients, serum testosterone decreased to castrate levels. Objective observations included uroflowmetry, measurement of residual urine volume, determination of prostatic size by ultrasonography, and prostatic biopsy. In all patients, the prostate regressed to a mean (±SEM) of 75.8 ± 3 percent of the initial size (range, 52 to 86,; P <0.005); the regression reached a plateau after four months. Morphologic analysis of biopsy specimens showed regression of glandular epithelium. Three of ninbe patients had clinical improvement with treatment. Six months after the cessation of treatment, plasma testosterone levels had returned to normal and the size of the prostate had increased to 99 ± 5.5 percent of the initial size. These findings suggest that androgens have an important supportive role in established benign prostatic hyperplasia and that testicular suppression will benefit some patients. However, this form of treatment could be applicable only in carefully selected patients who were not surgical candidates, and it would need to be maintained indefinitely.",
author = "Peters, {C. A.} and Patrick Walsh",
year = "1987",
language = "English (US)",
volume = "317",
pages = "599--604",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - The effect of nafarelin, acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

AU - Peters, C. A.

AU - Walsh, Patrick

PY - 1987

Y1 - 1987

N2 - We examined the influence of androgens on benign prostatic hyperplasia, using nafarelin acetate, a potent luteinizing-hormone-releasing hormone agonist, to achieve reversible androgen deprivation in men with benign prostatic hyperplasia. Nine patients with bladder-outlet obstruction due to benign prostatic hyperplasia were treated with subcutaneous nafarelin acetate (400 μg per day) in a open trial for six months. In all patients, serum testosterone decreased to castrate levels. Objective observations included uroflowmetry, measurement of residual urine volume, determination of prostatic size by ultrasonography, and prostatic biopsy. In all patients, the prostate regressed to a mean (±SEM) of 75.8 ± 3 percent of the initial size (range, 52 to 86,; P <0.005); the regression reached a plateau after four months. Morphologic analysis of biopsy specimens showed regression of glandular epithelium. Three of ninbe patients had clinical improvement with treatment. Six months after the cessation of treatment, plasma testosterone levels had returned to normal and the size of the prostate had increased to 99 ± 5.5 percent of the initial size. These findings suggest that androgens have an important supportive role in established benign prostatic hyperplasia and that testicular suppression will benefit some patients. However, this form of treatment could be applicable only in carefully selected patients who were not surgical candidates, and it would need to be maintained indefinitely.

AB - We examined the influence of androgens on benign prostatic hyperplasia, using nafarelin acetate, a potent luteinizing-hormone-releasing hormone agonist, to achieve reversible androgen deprivation in men with benign prostatic hyperplasia. Nine patients with bladder-outlet obstruction due to benign prostatic hyperplasia were treated with subcutaneous nafarelin acetate (400 μg per day) in a open trial for six months. In all patients, serum testosterone decreased to castrate levels. Objective observations included uroflowmetry, measurement of residual urine volume, determination of prostatic size by ultrasonography, and prostatic biopsy. In all patients, the prostate regressed to a mean (±SEM) of 75.8 ± 3 percent of the initial size (range, 52 to 86,; P <0.005); the regression reached a plateau after four months. Morphologic analysis of biopsy specimens showed regression of glandular epithelium. Three of ninbe patients had clinical improvement with treatment. Six months after the cessation of treatment, plasma testosterone levels had returned to normal and the size of the prostate had increased to 99 ± 5.5 percent of the initial size. These findings suggest that androgens have an important supportive role in established benign prostatic hyperplasia and that testicular suppression will benefit some patients. However, this form of treatment could be applicable only in carefully selected patients who were not surgical candidates, and it would need to be maintained indefinitely.

UR - http://www.scopus.com/inward/record.url?scp=0023227737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023227737&partnerID=8YFLogxK

M3 - Article

C2 - 2441256

AN - SCOPUS:0023227737

VL - 317

SP - 599

EP - 604

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -